TORONTO, March 27, 2026 (GLOBE NEWSWIRE)-- Profound Medical Corp. (NASDAQ:PROF; TSX:PRN) ("Profound" or the "Company"), a commercial-stage medical device company that develops and markets AI-powered, ...
There are several strategies for the early detection of prostate cancer. The first step is often a blood test for prostate-specific antigen (PSA). If PSA levels exceed a certain threshold, the next ...
Primary endpoint analysis at 1 year showed better maintenance of erectile function and pad-free continence with TULSA than with robotic radical prostatectomy. Peri-procedural metrics favored TULSA, ...
Using prostate MRI before a biopsy is a real advance in prostate cancer diagnosis. Multiple randomized trials have shown that imaging the prostate first and then targeting suspicious lesions finds ...
InvestorsHub on MSN
Profound Medical and Telix Pharmaceuticals partner to advance prostate cancer imaging and treatment education
Profound Medical (NASDAQ:PROF) and Telix Pharmaceuticals (NASDAQ:TLX) have signed a co-education agreement aimed at increasing physician awareness of how advanced diagnostic imaging can support ...
Collaboration will educate physicians and prostate cancer centers on the complementary roles of Telix’s PSMA-PET molecular imaging technologies ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results